Editor's note

Published July 2018. VacZine Analytics' commercial intelligence on Lassa fever vaccines is available in VAMV080 - MarketVIEW: Lassa Fever Vaccines, published July 2018.

Disease Background

Lassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), a single-stranded RNA virus of the Arenaviridae family. The virus, first identified in Nigeria in 1969, is zoonotic and mainly transmitted from the host, Mastomys natalensis (the multimammate rat), to humans. Symptoms range from fever, general malaise, weakness, and headache to the more severe outcomes of multi-organ failure or death. A significant cause of morbidity in survivors is deafness - permanent in approximately one-third of cases.

Pregnant women are particularly at risk. Intravenous ribavirin (if given early) can reduce mortality, but no licensed vaccine is available.

Annual burden · West Africa
100-300k

Estimated Lassa fever infections per year in West Africa, resulting in approximately 5,000 deaths. Estimates are considered outdated due to limited routine surveillance capacity.

The R&D Landscape

There are a number of prophylactic Lassa fever vaccine candidates in pre-clinical development supported by CEPI and WHO initiatives, but none yet at clinical stage at the time of this article. Organisations with an active interest in a Lassa fever vaccine include IAVI (rVSVdG/LVGPC), Themis Bioscience (measles vector), GeoVax (GEO-LM01), and Inovio (INO-4500).

"Almost 100% of fetuses are lost in LASV-infected pregnant women - a stark measure of disease severity in this particularly vulnerable population."

The Ebola Precedent

Ebola, a similar haemorrhagic fever virus, had recently been tackled in the Democratic Republic of Congo by a newly developed vaccine (VSV-EBOV) which received significant GAVI funding and interest from major manufacturers. As of June 2018, 2,295 people had been vaccinated in affected areas, including front-line health workers and contacts of confirmed cases. It is expected that a Lassa fever vaccine will be deployed in a similar ring vaccination strategy, but the higher and more sustained incidence of LASV infection - compared to Ebola outbreak dynamics - suggests a more preventative mass vaccination approach may ultimately be required.

VacZine Analytics' new MarketVIEW product (VAMV080) is a comprehensive executive presentation (~100 slides) and MS-Excel forecast model. It investigates the commercial potential of a putative Lassa fever vaccine across all relevant target groups in both preventative and emergency scenarios to 2035. The report includes a detailed Ebola vaccine procurement and deployment case study, a thorough review of disease background and epidemiology, and analysis of the competitive R&D environment.


This article is available in VacZine Analytics' Expert News archive as published in July 2018. For current intelligence on Lassa fever vaccines, see VAMV080.